Loading...
Loading...
Navidea Biopharmaceuticals, Inc.
NAVB, a biopharmaceutical
company focused on precision diagnostic radiopharmaceuticals, today
announced that it has reached agreement with the U.S. Food and Drug
Administration (FDA) for two special protocol assessments (SPA) for the
Company's pivotal Phase 3 program with NAV5001 as an aid in the
differential diagnosis of Parkinsonian Syndromes from non-Parkinsonian
tremor. NAV5001 is an investigational imaging agent used to visualize
dopamine transporters (DAT) in the brain using single photon emission
tomography (SPECT) imaging. The SPAs are written agreements between the
Company, as the program's sponsor, and FDA regarding the design,
endpoints and statistical analysis for the two pivotal Phase 3 clinical
trials to be used in support of a potential NAV5001 New Drug Application
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in